



INTERNATIONAL KIDNEY & MONOCLONAL GAMMOPATHY

RESEARCH GROUP
FOURTH INTERNATIONAL MEETING

MAY 23/24 – 2019

MONTREAL



www.ikmgresearchgroup.com

IKMG Research Group - 4th International Meeting

PROGRAM

SCIENTIFIC & ORGANIZING COMMITTEE

ROYAL Virginie, MD - Chair of the 4th IKMG Meeting
VENNER Christopher, MD – Co-chair of the 4th IKMG Meeting
BRIDOUX Frank, MD – IKMG President
LEUNG Nelson, MD – IKMG Past-President

LOCAL SCIENTIFIC COMMITTEE

BOLLÉE Guillaume, MD
GOUGEON François, MD
LEBLANC Richard, MD
LEFEBVRE Joannie, MD
LEMIEUX-BLANCHARD Émilie, MD
PELLETIER Karyne, MD
TROYANOV Stéphan, MD

GENERAL OBJECTIVES

1. Identify progress and provide update in the field of monoclonal gammopathy-associated kidney diseases.
2. Evaluate recent research work in the field of monoclonal gammopathy-associated kidney diseases.
3. Encourage collaboration between investigators for current and future endeavours.
4. Recognize the importance of interdisciplinary work in monoclonal gammopathy-associated kidney diseases and provide an environment that nurtures collaboration between clinicians.

In keeping with the required standards, each of the short 10-minute presentations will be followed by a 5-minute question period, and each of the 30-to-45-minute presentations, with a 10-minute question period. In addition, all presentations will be evaluated by participants.

TARGET POPULATION

This activity is for medical specialists including Nephrologists, Hematologists and Pathologists, physicians and specialists in other disciplines, residents - nephrology, pathology, hematology programs and residents of other disciplines as well as researchers, professionals, health care workers involved in the field of monoclonal gammopathy-associated kidney diseases.

ACCREDITATION

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program (MOC) of the Royal College of Physicians and Surgeons of Canada, and approved by the Continuing Professional Development Directorate (CPDD) of the Fédération des médecins spécialistes du Québec.

You may claim up to 13,75 hours for this activity (credits are automatically calculated in MAINPORT). Participation in this activity qualifies for a certificate of attendance. Participants should claim a number of hours consistent with their attendance.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association (AMA), physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

7:00 am: **Registration and Breakfast**

8:00 am: **Opening remarks**
Frank Bridoux, Virginie Royal

8:15 am: MGRS-related kidney diseases
Chairs: Pierre Ronco, Richard Leblanc

1. Updated classification of MGRS-associated kidney diseases: Nelson Leung

At the end of the session, the participant will be able:

- To name the hematological presentations included in the diagnosis of MGRS
- To classify renal diseases associated with MGRS.
- To list the entities recently included in the spectrum of MGRS-associated kidney diseases.

2. State of the art of the techniques for the diagnosis of M-Ig related kidney diseases: Vivette D'Agati

At the end of the session, the participant will be able:

- To list the different techniques used in pathology for the diagnosis of MGRS-associated renal diseases.
 - To highlight the value of high quality immunofluorescence and electron microscopy in the diagnosis of MGRS-associated renal diseases.
-

9:15 am: Proliferative Glomerulonephritis with non-organized monoclonal immunoglobulin deposits (PGNMID);
Chairs: Glen Markovitz, Julie Riopel

1. Pathology of PGNMID: Samih Nasr

At the end of the session, the participant will be able:

- To describe the histological patterns of PGNMID
- To name the new morphological entities included in the spectrum of PGNMID

2. Clinical and hematological characteristics of PGNMID: Jonathan Hogan

At the end of the session, the participant will be able:

- To identify the clinical features and haematological presentations of patients with PGNMID
- To manage diagnostic workup in patients with a diagnosis of PGNMID

3. Update on treatment of PGNMID: Nelson Leung

At the end of the session, the participant will be able:

- To recall and explain current therapeutic options of PGNMID
 - To describe new therapeutic strategies in the treatment of PGNMID and their expected benefits.
-

10:45 am: **Break**

11: 00 am: Cast Nephropathy;
Chairs: Jean-Paul Ferman, Karyne Pelletier

1. Pathology of cast nephropathy: Virginie Royal

At the end of the session, the participant will be able:

- To describe the histological spectrum of myeloma cast nephropathy
- To describe the prognostic value of renal biopsy in diagnosis of cast nephropathy

2. Current criteria for renal response in cast nephropathy: Efstathios Kastiris

At the end of the session, the participant will be able:

- To recall current clinical criteria used for measuring renal response in cast nephropathy
- To recognize the limitations of current criteria for measuring renal response in cast nephropathy
- To describe alternative approaches for measuring renal response

3. Treatment of cast nephropathy/MYRE study: Frank Bridoux

At the end of the session, the participant will be able:

- To explain current treatment strategies in cast nephropathy
 - To describe the study design of the MYRE study.
 - To discuss the results of the MYRE study.
-

12:30 pm: **Lunch**

2:00 pm: **Biological and diagnosis;**
Chairs: Abhijat Kitchlu, Joannie Lefebvre

- 1. Update on monoclonal protein detection/measurement: Mass spectrometry: David Murray**
At the end of the session, the participant will be able:
 - To discuss the current status in the field of the detection of serum free light chains
 - To describe novel serum free light chain detection methods and their utility
- 2. Proteomics in the diagnosis of Monoclonal Immunoglobulin related kidney diseases: Surendra Dasari**
At the end of the session, the participant will be able:
 - To recognize the value of proteomics in the diagnosis of renal disease associated with monoclonal immunoglobulin.
 - To briefly describe the technique of laser microdissection and mass spectrometry used for the diagnosis of renal disease associated with monoclonal immunoglobulin.
- 3. Immunoglobulin Repertoire Sequencing (RepSeq): A new tool for diagnosis and treatment follow-up in monoclonal gammopathy of clinical significance: Christophe Sirac**
At the end of the session, the participant will be able:
 - To briefly describe the Immunoglobulin Repertoire Sequencing (RepSeq) technique.
 - To list the clinical applications of the RepSeq technique in current medical practice.

3:30 pm: **Break**

4:00 pm: **Oral Communications;**
Chairs: Guy Touchard, Stéphan Toyanov

- At the end of the session, the participant will be able:
- To identify and discuss the latest advances in research in the field of monoclonal gammopathy-related renal diseases
 - To highlight the importance of multidisciplinary work in research in the field of monoclonal gammopathy-related renal diseases

6:00 pm: **Reception and Posters**
8:00 pm: **Dinner**

Friday, May 24, 2019

7:00 am: **Breakfast**

8:00 am: **Basic Science;**
Chairs: Maria Picken, François Gougeon

- 1. Exosomes and residual disease in AL amyloidosis: Marina Ramirez Alvarado**
At the end of this session, the participant will be able:
 - To describe the utility of urinary extracellular vesicles to determine minimal residual kidney disease in AL amyloidosis
 - To list the technical considerations associated with the measurement of residual kidney diseases by quantitative comparison of urinary extracellular vesicles
- 2. Understanding mesangial damage and repair in light-chain associated mesangiopathy: Guillermo Herrera**
At the end of this session, the participant will be able:
 - To briefly describe the interaction of light chains with mesangial cells and mesangial matrix in AL amyloidosis and light chain deposition disease.
 - To explain cellular mechanisms of mesangial repair in light chain deposition disease and AL amyloidosis
- 3. C3 Glomerulonephritis, Thrombotic Microangiopathy and Monoclonal Immunoglobulin: Sophie Chauvet**
At the end of this session, the participant will be able:
 - To briefly describe the pathophysiology of the alternative complement pathway
 - To describe the involvement of the alternative complement pathway in renal diseases associated with monoclonal gammopathy
- 4. Physiopathology of Cast Nephropathy: Paul Sanders**
At the end of this session, the participant will be able:
 - To describe the pathophysiology of myeloma cast formation in the distal tubule
 - To list the systemic and local factors associated with cast formation

10:30 am: **Break**

10:45 am: **Amyloidosis;**

Chairs: Vecihi Batuman, Émilie Lemieux-Blanchard

1. Pitfalls in the diagnosis of AL amyloidosis: Ashutosh Wechalekar

At the end of this session, the participant will be able:

- To review current diagnostic approaches for AL amyloidosis
- To recognize the diagnostic challenges and limitations of current available modalities for the detection of AL amyloidosis
- To highlight the importance of subtyping amyloidosis for both prognostic and therapeutic purposes
- To provide insight into future technologies and approaches for the diagnosis of AL amyloidosis

2. Update on treatment of AL amyloidosis: Arnaud Jaccard

At the end of this session, the participant will be able:

- To review current therapeutic strategies in AL amyloidosis
- To describe novel therapeutic approaches for the treatment of AL amyloidosis

3. Organ transplantation in AL amyloidosis: Andrea Havasi

At the end of this session, the participant will be able:

- To briefly describe the current status in the field of organ transplantation in patients with amyloidosis AL
- To describe current knowledge on renal outcome of kidney transplant patients with AL amyloidosis

12:30 pm: **Lunch**

2:00 pm: **The Future;**

Chairs: Jean-Samuel Boudreault-Pednault, Nelson Leung

1. Overview of novel treatments in Multiple Myeloma: Christopher Venner

At the end of this session, the participant will be able:

- To briefly review current therapeutic agents in the treatment of Multiple Myeloma
- To describe novel therapeutic approaches in the treatment of Multiple Myeloma

2. Monoclonal Gammopathy of Clinical Significance: Jean-Paul Fermanand

At the end of this session, the participant will be able:

- To define the concept of monoclonal gammopathy of clinical significance
- To recognize the clinical and therapeutic implications of a diagnosis of MGCS.

3:15 pm: **IKMG future directions and closing remarks**

Frank Bridoux, Virginie Royal

3:45 pm: **Break**

4-6:00 pm: **Board meeting**

THANKS

This program is made possible through an unrestricted grant from:

PLATINE
AMGEN
CELGENE
JANSSEN
TAKEDA
THE BINDING SITE

SILVER
MYELOME CANADA

as well as a contribution of TOURISME MONTREAL

This event is supported by:

